March 28 (Reuters) - Cardinal Health Inc is exploring a potential sale of its nuclear medicine unit as part of a larger review of its business, Bloomberg News reported on Tuesday, citing people familiar with the matter.

The Dublin, Ohio-based drug distributor has been in talks with advisers to examine interest in the unit, which makes radioactive agents and drugs that doctors use to diagnose and treat diseases such as cancer, the report said.

While a final decision is yet to be made, several private equity firms have been mulling offers for the business that could fetch a value of more than $1 billion in a sale, sources told Bloomberg.

The company did not immediately respond to a Reuters request for comment.

(Reporting by Priyamvada C in Bengaluru; Editing by Devika Syamnath)